Clinical Features and HSCT Outcome for SCID in Turkey


Ikinciogullari A., Cagdas D., Dogu F., Tugrul T., Karasu G., Haskologlu S., ...More

JOURNAL OF CLINICAL IMMUNOLOGY, vol.39, no.3, pp.316-323, 2019 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 3
  • Publication Date: 2019
  • Doi Number: 10.1007/s10875-019-00610-x
  • Journal Name: JOURNAL OF CLINICAL IMMUNOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.316-323

Abstract

Severe combined immunodeficiency (SCID) is the most serious PID, characterized by T cell lymphopenia and lack of antigen-specific T cell and B cell immune responses, inevitably leading to death within the first year of life if hematopoietic stem cell transplantation (HSCT) is not performed.